OBI Pharma, Inc. (TPEX:4174)

Market Cap	3.76B -62.3%
Revenue (ttm)	49.68M -26.9%
Net Income	-1.98B
EPS	-15.78
Shares Out	131.58M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	312,569
Open	28.35
Previous Close	28.20
Day's Range	28.30 - 28.90
52-Week Range	28.05 - 73.50
Beta	0.11
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About OBI Pharma

OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company’s pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of so...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4174

Financial Performance

In 2025, OBI Pharma's revenue was 58.58 million, a decrease of -6.55% compared to the previous year's 62.68 million. Losses were -2.05 billion, -11.13% less than in 2024.